A Study of Combination Therapy in Children With ADHD

NCT ID: NCT01940978

Last Updated: 2015-04-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 99 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-31
• Study Completion Date: 2015-03-31

Brief Summary

Lack of appetite and weight loss are a common side effect of ADHD therapy with amphetamines such as methylphenidate. Lack of sufficient food intake has been shown to have negative effects on weight and height as well as learning and memory.

There is no current treatment to prevent this loss of appetite except discontinuation or reduction of the methylphenidate. Discontinuation or reduction of the drug can cause the return of ADHD symptoms.

The purpose of this study is to compare the effects, good and/or bad, of two doses of a drug, cyproheptadine, vs placebo to find out if cyproheptadine prevents the appetite suppression associated with methylphenidate.

Conditions

ADHD; Attention Deficit Hyperactivity Disorder; Attention Deficit Disorder With Hyperactivity; Mental Disorders Diagnosed in Childhood; Attention Deficit and Disruptive Behavior Disorders

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Control

Methylphenidate ER QD placebo BID

Group Type: PLACEBO_COMPARATOR

Methylphenidate ER

Intervention Type: DRUG

Watson generic, starting dose 18mg QD

Methylphenidate ER, cyproheptadine 2.5mg

Methylphenidate ER QD cyproheptadine hydrochloride 2.5mg BID

Group Type: ACTIVE_COMPARATOR

Methylphenidate ER

Intervention Type: DRUG

Watson generic, starting dose 18mg QD

Cyproheptadine

Intervention Type: DRUG

cyproheptadine hydrochloride

Methylphenidate ER, cyproheptadine 5mg

Methylphenidate ER QD cyproheptadine hydrochloride 5.0mg BID

Group Type: ACTIVE_COMPARATOR

Methylphenidate ER

Intervention Type: DRUG

Watson generic, starting dose 18mg QD

Cyproheptadine

Intervention Type: DRUG

cyproheptadine hydrochloride

Interventions

Methylphenidate ER

Watson generic, starting dose 18mg QD

Intervention Type: DRUG

Cyproheptadine

cyproheptadine hydrochloride

Intervention Type: DRUG

Other Intervention Names

Concerta; Periactin

Eligibility Criteria

Inclusion Criteria

• The subject and subject's parents speak English
• Child or adolescent patients, male or female outpatients, who are at least 6 years of age, but must not yet have reached their 13th birthday prior to Visit 1, when informed consent is obtained
• Patients must meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) diagnostic criteria for ADHD (any subtype) and score at least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the Swanson, Nolan and Pelham Questionnaire: Attention-Deficit/Hyperactivity Disorder Subscale (SNAP-IV ADHD Subscale) score at both Visit 1 and 2
• Laboratory results, including serum chemistries, hematology, and urinalysis, must show no clinically significant abnormalities (clinically significant is defined as laboratory values requiring acute medical intervention, indicating a serious medical illness, or requiring further medical evaluation in the judgment of the investigator)
• Patients and parents have been judged by the investigator to be reliable to keep appointments for clinic visits and all tests, including venipuncture, and examinations required by the protocol.
• Patient has not been on stimulants for at least 2 weeks.

Exclusion Criteria

• Patients who have a documented history of Bipolar I or II disorder, or any history of psychosis. Diabetic patients or patients on chronic steroids.
• Patients with a history of any seizure disorder (other than febrile seizures) or patients who have taken (or are currently taking) anticonvulsants for seizure control are not eligible to participate
• Patients at serious suicidal risk as defined by 1) suicidal ideation as endorsed on items 4 and 5 of the C-SSRS within the past year, 2) suicidal behaviors detected by the C-SSRS during the past two years; or 3) psychiatric interview and examination
• Patients with significant cardiovascular disease or other conditions that could be aggravated by an increased heart rate or increased blood pressure
• Patients who have any medical condition that would increase sympathetic nervous system activity markedly (for example, catecholamine-secreting neural tumor), or who are taking a medication on a daily basis (for example, albuterol, inhalation aerosols, pseudoephedrine), that has sympathomimetic activity. Such medications can be taken on an as-needed basis
• Presence of contraindications for methylphenidate or cyproheptadine hydrochloride
• Patients who have had prior serious adverse reaction to stimulants.
• Parental or (immediate) family history of substance abuse

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Douglas Sears

INDIV

Sponsor Role: lead

Responsible Party

Douglas Sears

Douglas Sears, MD

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Jose M Schuster, MD

Role: PRINCIPAL_INVESTIGATOR

SMRI

Locations

SMRI (Schuster Medical Research Institute)

Van Nuys, California, United States

Countries

United States

Other Identifiers

001

Identifier Type: -

Identifier Source: org_study_id